Japan Tobacco Inc.

Dai Motoda

Kazuhito Ueyama

Hiroyuki Abe

Masahiro Yokota

Koichi Suzawa

Yosuke Ogoshi

Kazuyuki Sugimoto

Masahiro Tanaka

Hiroshi Ueno

Hironobu Nagamori

Makoto Shiozaki

Akihiko Takahashi

Ikuo Mitani

Tomoya Miura

Kiyosei Iio

Akira Suma

Takahiro Hotta

Masakazu Terashita

Takuya Matsui

Nobutaka Yamaoka

Ritsuki Masuo

Masayuki Kotoku

Takaki Maeba

Toshihiko Iwayama

Satoki Doi

Junichiro Tsuruha

Tsuyoshi Adachi

Toru Noguchi

Takashi Ito

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof: wherein each symbol means the same as that described in the specification.

Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof

The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.

Pyrazole compound and pharmaceutical use thereof

The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent

The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

Piperazine compound and use thereof as a HCV polymerase inhibitor

Growing community of inventors

Takatsuki, Japan

Dai Motoda